aTyr Pharma (ATYR) Stock Price, News & Analysis

Company Overview

aTyr Pharma, Inc. (NASDAQ: ATYR) is a biotechnology company focused on developing therapies that modulate immune responses and address serious inflammatory diseases. The company’s research is based on its Physiocrine biology platform, which explores the therapeutic activity of extracellular domains of tRNA synthetases, a group of proteins involved in regulating biological processes beyond protein synthesis.

aTyr’s lead product candidate is efzofitimod, an engineered version of a naturally occurring protein intended to regulate immune-cell activity and reduce inflammation. The candidate has been studied primarily as an inhaled treatment for pulmonary sarcoidosis, a rare inflammatory lung disease, and has also been evaluated in other interstitial lung disease settings, including systemic sclerosis-associated interstitial lung disease.

Founded in 2005 and headquartered in San Diego, California, aTyr conducts research and clinical development activities through collaborations and clinical studies involving patients and medical institutions in the United States and other regions. The company is led by Sanjay S. Shukla, M.D., M.S., who serves as president and chief executive officer.

Key Stats

• Today's Range: $0.36 to $0.39
• 50-Day Range: $0.36 to $0.57
• 52-Week Range: $0.36 to $1.12
• Volume: 1.26 million shs
• Average Volume: 742,724 shs
• Market Capitalization: $35.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

aTyr Pharma Stock Analysis - MarketRank™

aTyr Pharma scored higher than 12% of companies evaluated by MarketBeat, and ranked 847th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

aTyr Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

aTyr Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for aTyr Pharma are expected to decrease in the coming year, from ($0.44) to ($0.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of aTyr Pharma is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of aTyr Pharma is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

aTyr Pharma has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.04% of the float of aTyr Pharma has been sold short.

Short Interest Ratio / Days to Cover

aTyr Pharma has a short interest ratio ("days to cover") of 16.07, which indicates bearish sentiment.

Change versus previous month

Short interest in aTyr Pharma has recently decreased by 1.72%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

aTyr Pharma does not currently pay a dividend.

Dividend Growth

aTyr Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for aTyr Pharma this week, compared to 7 articles on an average week.

Search Interest

10 people have searched for ATYR on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.

MarketBeat Follows

6 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, aTyr Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.75% of the stock of aTyr Pharma is held by insiders.

Percentage Held by Institutions

61.72% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ATYR
• Previous Symbol: NASDAQ:ATYR
• CIK: 1339970
• Web: atyrpharma.com
• Phone: (858) 731-8389
• Fax: 858-731-8394
• Employees: 58
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): ($0.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.12 million
• Net Margins: N/A
• Pretax Margin: -32,006.32%
• Return on Equity: -95.89%
• Return on Assets: -69.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.12
• Quick Ratio: 5.12

Sales & Book Value

• Annual Sales: $190 thousand
• Price / Sales: 187.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 98,090,000
• Free Float: 92,447,000
• Market Cap: $35.61 million
• Optionable: Optionable
• Beta: 0.53